Development of candidate genomic markers to select breast cancer patients for dasatinib therapy

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1120-1127

  Moulder, Stacy ^a   Yan, Kai ^a   Huang, Fei ^b   Hess, Kenneth R ^a   Liedtke, Cornelia ^c   Lin, Feng ^a   Hatzis, Christos ^d   Hortobagyi, Gabriel N ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d Nuvera Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG INDICATION; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MARKER GENE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENOME, HUMAN; HUMANS; MATCHED-PAIR ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PROGNOSIS; PYRIMIDINES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 77952114407     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1117     Document Type: Article

References (27)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874
2. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
3. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
4. Yu K, Lee CH, Tan PH, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004;64:2962-2968
5. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-226
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826
7. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-2293 (Pubitemid 41115384)
8. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-4244
9. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6086 (Pubitemid 350075065)
10. Fin RS BC, Ibrahim N, Strauss SC, et al. Phase II trial of dasatinib in triple negative breast cancer: results of study CA180059. 2008 San Antonio Breast Cancer Symposium. abstract 3118.
11. http://clinicaltrials.gov/ct2/show/NCT00780676?term=dasatinib&recr= Open&rslt=Without&type=Intr&rank=16.
12. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357
13. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-2238 (Pubitemid 46424242)
14. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-11016
15. http://bioinformatics.mdanderson.org/pubdata.html.
16. http://cancer.lbl.gov/breastcancer/data.php.
17. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527
18. Slonim DK, Tamayo P, Mesirov JP, Golub TR, Lander ES. Class prediction and discovery using gene expression data. In Proceedings of the Fourth Annual International Conference on Computational Molecular Biology (RECOMB) 2000;2000:263-272
19. In: Hollander M, Wolfe DA, editors. Nonparametric Statistical Methods. 2nd ed New York: Wiley; 1999.
20. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2001.
21. Meyer D, Leisch F, Hornik K. The support vector machine under test. Neurocomputing 2003;55:169-186
22. Chang CC, Lin CJ. LIBSVM: a library for support vector machines. 2001. Software available from: http://www.csie.ntu.edu.tw/~cjlin/libsvm.
23. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61 Suppl 2:14-21.
24. Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat 2008;11:99-109.
25. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406-2415
26. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003;97:2960-2971
27. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527 (Pubitemid 351655218)